Many historical drug failures can be attributed to problems in pharmacokinetics and bioavailability. It is possible to minimize the risk of such failures by using various in vitro assays that help at an early stage to identify molecules with better absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics.
In order to support its medicinal chemistry programs, Evotec has developed a suite of in vitro assays that can be used to identify potential liabilities in early-stage compounds and to support the design of improved compounds during lead optimization. Evotec also provides ADMET services on a stand-alone, compound basis.
Evotec can also perform bioanalysis to generate and interpret typical parameters such as bioavailability, AUC, MRT, half-life, clearance and volume of distribution.
Evotec has the following capabilities:
- In silico predictive models for ADMET (EVOseek™)
- In vitro ADMET assays
- Electrophysiology & hERG Assays
For more information, please contact us at firstname.lastname@example.org